Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of trastuzumab deruxtecan versus physician's choice in HER2-low advanced breast cancer
CTR20191730Phase 3Active
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab deruxtecan in breast cancer, sponsored by Daiichi Sankyo Co., Ltd.. Started Dec 2019; status: active.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20191730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191730.